GLP-1
Effective treatments for diabetes are becoming more and necessary. The past few years have demonstrated productive strides in drug therapies, such as following medications.
A consortium jointly led by Astorg and Cinven announces that it has signed an agreement to acquire LGC, a global leader in the Life Sciences Tools sector.
Trulicity was approved by the U.S. Food and Drug Administration in September 2014.
Administered once-daily, SOLIQUA® allows patients with uncontrolled type 2 diabetes take charge of their long-term health
NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate under their existing license and collaboration agreement.
Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB group.
Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.
Several recent studies that aren’t on laboratory animals per se, but species-specific biological research, have been shown to have far-reaching implications for human beings.
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
PRESS RELEASES